Comparing Prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins Glypican-3, Alpha feto protein and Carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients

Journal of the Egyptian National Cancer Institute

Volumn 26, Issue 2, 2014, Pages 79-85

  Abd El Gawad, Iman A ^a,b   Mossallam, Ghada I ^a   Radwan, Noha H ^a   Elzawahry, Heba M ^a   Elhifnawy, Niveen M ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b The Department of Medical Oncology NCI Cairo University ^*  (United States)

Author keywords

AFP; CEA; GPC 3; HCC; Oncofetal antigens; PIVKA II

Indexed keywords

ALPHA FETOPROTEIN; CARCINOEMBRYONIC ANTIGEN; GLYPICAN 3; PROTHROMBIN; PROTHROMBIN INDUCED BY VITAMIN K ABSENCE II; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; GLYPICAN; PROTEIN PRECURSOR; TUMOR MARKER; VITAMIN K GROUP;

ADULT; AGED; ARTICLE; ASCITES; BENIGN TUMOR; BLOOD SAMPLING; CANCER PATIENT; CANCER PROGNOSIS; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; EGYPT; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATOMEGALY; HUMAN; IMMUNOASSAY ANALYZER; LABORATORY DIAGNOSIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FUNCTION TEST KIT; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN THROMBOSIS; SENSITIVITY AND SPECIFICITY; SPLENOMEGALY; BLOOD; CARCINOMA, HEPATOCELLULAR; DIAGNOSTIC USE; LIVER NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; CANCER DIAGNOSIS; COMPARATIVE STUDY; EGYPTIAN; TUMOR VOLUME;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, HEPATOCELLULAR; FEMALE; GLYPICANS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROTEIN PRECURSORS; PROTHROMBIN; TUMOR MARKERS, BIOLOGICAL; VITAMIN K;

EID: 84900496283     PISSN: 11100362     EISSN: 16879996     Source Type: Journal    
DOI: 10.1016/j.jnci.2014.01.001     Document Type: Article

References (40)

1. Jain S., Singhal S., Lee P., Xu R. Molecular genetics of hepatocellular neoplasia. Am J Transl Res 2010, 2(1):105-118.
2. NCI Cancer Registry, Cairo: Cancer Registry, 2002-2007. Website:. http://www.nci.edu.eg.data.
3. Sakamoto M., Mori T., Masugi Y., Effendi K., Rie I., Du W. Candidate molecular markers for histological diagnosis of early hepatocellular carcinoma. Intervirology 2008, 51(S1):42-45.
4. Marrero J., Feng Z., Wang Y., Nguyen M., Befeler A., Roberts L.R., et al. Alfa-feto protein, des-gamma carboxy prothrombin, and lectin-bound alpha-feto protein in early hepatocellular carcinoma. Gastroenterology 2009, 137(1):110-118.
5. Treviasiani F., D'Intino P.E., Morselli-Labate A.M., Mazzella G., Accogli E., Caraceni P., et al. Serum AFP for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HbSAg and anti-HCV status. J Hepatol 2001, 34(4):570-575.
6. Taketa K. Alpha-fetoprotein (reevaluation in hepatology). Hepatology 1990, 12(6):1420-1432.
7. Johnson J. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001, 5(1):145-159.
8. Kandil D., Cooper K. Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol 2009, 16(2):125-129.
9. Liu H., Li P., Zhai Y., Qu C., Zhang L., Tan Y., et al. Diagnostic value of Glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010, 16(35):4410-4415.
10. Youssef M., El-Sharkawy S., Abbas N., El-Shinnawy S., El-Hadidi E., Shahin R., et al. Clinical utility of Glypican-3 in hepatocellular carcinoma. Int J Integr Biol 2010, 10(1):41-47.
11. Suriawinata A., Thung S.N. Molecular signature of early hepatocellular carcinoma. Oncology 2010, 78(Suppl.):36-39.
12. Gomaa A., Hendy O., Aboraia G., Attia H., Elezawy H., Nafei E., et al. The diagnostic value of peripheral blood Glypican-3 in patients with hepatocellular carcinoma. World J Med Sci 2012, 7(2):105-112.
13. Hansen J., Snyder J., Miller E., Vandevoorde P., Miller N., Hines R., et al. Carcinoembryonic antigen (CEA) assay: a laboratory adjunct in the diagnosis and management of cancer. Hum Pathol 1974, 5:139-147.
14. Volk L., Hernandez C., Su L., Lok S., Marrero A. Risk factors for hepatocellular carcinoma may impair the performance of biomarkers: a comparison of AFP, DCP, and AFP-L3. Cancer Biomarkers 2007, 3:79-87.
15. Sharma B., Srinivasan R., Chawla Y.K., Kapil S., Saini N., Singla B., et al. Clinical utility of prothrombin induced by vitamin K absence in the detection of hepatocellular carcinoma in Indian population. Hepatol Int 2010, 4(3):569-576.
16. Zachary, Khodeer S, Ezzat H, Abdel Malak C. Impact of PIVKA-II in diagnosis of hepatocellular carcinoma. International Conference on Ecological, Environmental and Biology Sciences (ICEEBS' 2012), Jan. 7-8. 2012 Dubai.
17. Choi J., Jung S., Kim H., Kim M., Kim Y., Kim D., et al. Diagnostic value of AFP and PIVKA-II in HCC according to total-AFP. World J Gastroenterol 2013, 19(3):339-346.
18. Poller L. The prothrombin time 1998; World Health Organization/Health Laboratory Technology unit LAB/98.3. http://www.who.int/iris/handle/10665/63996.
19. Silver K., Gold P., Feder S., Freedman O., Shuster J. Radioimmunoassay for Human Alpha-1 Fetoprotein. Proc Natl Acad Sci USA 1973, 70(2):526-530.
20. Hansen J., LaFontaine G., Newman S., Schwartz K., Malkin A., Mojzisik K., et al. Solving the problem of antibody interference in commercial "sandwich"-type immunoassays of carcinoembryonic antigen. Clin Chem 1989, 35:146-151.
21. Mizokami M., Tanaka Y. Tracing the evolution of hepatitis C virus in the United States, Japan and Egypt by using the molecular clock. Clin Gastroenterol Hepatol 2005, 3(10 Suppl 2):82-85.
22. Yao F., Dong Z., Yao M. Specific markers in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2007, 6:241-247.
23. Nakatsura T., Yoshitake Y., Senju S., Monji M., Komori H., Motomura Y., et al. Glypican 3, overexpressed specifically in human hepatocellular carcinoma is a novel tumor marker. Biochem Biophys Res Commun 2003, 306(1):16-25.
24. Shafizadeh N., Ferrel P., Karkar S. Utility and limitation of Glypican-3 expression for the of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol 2008, 21(8):1011-1018.
25. Hippo Y., Watanabe K., Watanabe A., Midorikawa Y., Yamamoto S., Ihara S. Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res 2004, 64:2418-2423.
26. Iglesias V., Centeno G., Pascucceli H., Ward F., Peter G., Filmus J., et al. Expression pattern of glypican-3 (GPC-3) during human embryonic and fetal development. Histol Histopathol 2008, 23(11):1333-1340.
27. Ozkan H., Erdal H., Koçak E., Tutkak H., Karaeren Z., Yakut M., et al. Diagnostic and prognostic role of serum glypican3 in patients with hepatocellular carcinoma. J Clin Lab Anal 2011, 25(5):350-353.
28. El-Shenawy S., El Sabawi M., Sheble N., Abd El-Raof M., Allam M., Fath Allah S. Diagnotic role of serum Glypican-3 as a tumor marker for hepatocellular carcinoma. Nat Sci 2012, 10(4):32-38.
29. Hassan M., Zaghloul A., El-Serag H., Soliman O., Patt Y., Chappell C., et al. The role of hepatitis C in hepatocellular carcinoma: a case control study among Egyptian patients. J Clin Gastroenterol 2001, 33(2):123-126.
30. Liu H., Li P., Zhai Y., Qu C., Zhang L., Tan Y., et al. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol 2010, 16(35):4410-4415.
31. Capurro M., Wanless I., Sherman M., Deboer G., Shi W., Miyoshi E. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology 2003, 125:89-97.
32. Kim H., Park J., Jang J., Kim H., Shin W., Kim K., et al. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. J Clin Gastroenterol 2009, 43(5):482-488.
33. Baek Y., Lee J., Jang J., Lee S., Han J., Jeong J., et al. Diagnostic role and correlation with staging systems of PIVKA-II compared with AFP. Hepatogastroenterology 2009, 56(91-92):763-767.
34. Singhal A., Jayaraman M., Dhanasekaren D., Kohli V. Molecular and serum markers in hepatocellular carcinoma: predictive tools for prognosis and recurrence. Oncol Hematol 2012, 82(2):116-140.
35. Cheng W., Tseng C., Lin T., Cheng I., Pan H., Hsu H., et al. Glypican-3-mediated oncogenesis involves the insulin-like growth factor-signaling pathway. Carcinogenesis 2008, 29(7):1319-1326.
36. Jackbovic B., Jothy S. Glypican-3 from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol 2007, 82(2):184-189.
37. Zhou L., Liu J., Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006, 12(8):1175-1181.
38. Tangkijvanich P., Chanmer T., Komtong S., Mahachai V., Wisedopas N., Pothacharoen P., et al. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol 2010, 25:129-137.
39. Poon D., Anderson B., Chen L., Tanaka K., Lau W., Van Cutsem E. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009, 10(11):1111-1118.
40. Stefaniuk P., Cianciara J., Wiercinska-Drapalo A. Present and future possibilities for early diagnosis of hepatocellular carcinoma. World J Gastroenterol 2010, 16(4):418-424.